Public Employees Retirement System of Ohio Acquires 38,049 Shares of Halozyme Therapeutics, Inc. $HALO

Public Employees Retirement System of Ohio boosted its position in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 6,594.3% during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 38,626 shares of the biopharmaceutical company's stock after purchasing an additional 38,049 shares during the period. Public Employees Retirement System of Ohio's holdings in Halozyme Therapeutics were worth $2,009,000 as of its most recent SEC filing.

Other hedge funds also recently added to or reduced their stakes in the company. Wealth Preservation Advisors LLC bought a new position in Halozyme Therapeutics during the 1st quarter valued at about $32,000. SVB Wealth LLC bought a new position in Halozyme Therapeutics during the 1st quarter valued at about $33,000. Bessemer Group Inc. grew its holdings in Halozyme Therapeutics by 62.9% during the 1st quarter. Bessemer Group Inc. now owns 536 shares of the biopharmaceutical company's stock valued at $34,000 after purchasing an additional 207 shares during the last quarter. Brooklyn Investment Group grew its holdings in Halozyme Therapeutics by 1,558.1% during the 1st quarter. Brooklyn Investment Group now owns 713 shares of the biopharmaceutical company's stock valued at $45,000 after purchasing an additional 670 shares during the last quarter. Finally, Park Place Capital Corp grew its holdings in Halozyme Therapeutics by 20.1% during the 1st quarter. Park Place Capital Corp now owns 1,086 shares of the biopharmaceutical company's stock valued at $69,000 after purchasing an additional 182 shares during the last quarter. 97.79% of the stock is currently owned by institutional investors.

Halozyme Therapeutics Price Performance

Shares of HALO opened at $71.69 on Friday. The company has a 50 day moving average price of $70.23 and a 200-day moving average price of $61.92. Halozyme Therapeutics, Inc. has a fifty-two week low of $42.01 and a fifty-two week high of $79.50. The stock has a market capitalization of $8.39 billion, a PE ratio of 16.41, a PEG ratio of 0.41 and a beta of 1.16. The company has a debt-to-equity ratio of 4.54, a quick ratio of 7.01 and a current ratio of 8.36.

Halozyme Therapeutics (NASDAQ:HALO - Get Free Report) last announced its quarterly earnings results on Tuesday, August 5th. The biopharmaceutical company reported $1.54 earnings per share for the quarter, topping the consensus estimate of $1.23 by $0.31. Halozyme Therapeutics had a net margin of 47.28% and a return on equity of 150.85%. The firm had revenue of $325.72 million during the quarter, compared to analysts' expectations of $282.66 million. During the same quarter in the prior year, the company earned $0.91 EPS. The company's revenue was up 40.8% compared to the same quarter last year. Halozyme Therapeutics has set its FY 2025 guidance at 6.000-6.400 EPS. Equities analysts predict that Halozyme Therapeutics, Inc. will post 4.73 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

HALO has been the topic of several analyst reports. Benchmark upped their price target on shares of Halozyme Therapeutics from $75.00 to $90.00 and gave the company a "buy" rating in a report on Wednesday, September 24th. Wall Street Zen cut shares of Halozyme Therapeutics from a "strong-buy" rating to a "buy" rating in a research report on Friday, September 5th. HC Wainwright boosted their price objective on shares of Halozyme Therapeutics from $85.00 to $90.00 and gave the company a "buy" rating in a research report on Thursday. Zacks Research raised shares of Halozyme Therapeutics from a "hold" rating to a "strong-buy" rating in a research report on Tuesday, September 2nd. Finally, The Goldman Sachs Group started coverage on shares of Halozyme Therapeutics in a research report on Thursday, July 10th. They issued a "neutral" rating and a $55.00 price objective for the company. One research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, four have assigned a Hold rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Hold" and an average target price of $70.44.

Insider Transactions at Halozyme Therapeutics

In other news, Director Bernadette Connaughton sold 2,000 shares of the company's stock in a transaction that occurred on Wednesday, October 1st. The shares were sold at an average price of $75.24, for a total value of $150,480.00. Following the completion of the sale, the director owned 44,952 shares of the company's stock, valued at approximately $3,382,188.48. This represents a 4.26% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Helen Torley sold 20,000 shares of the business's stock in a transaction that occurred on Wednesday, September 3rd. The stock was sold at an average price of $74.44, for a total transaction of $1,488,800.00. Following the transaction, the chief executive officer owned 733,719 shares of the company's stock, valued at approximately $54,618,042.36. This trade represents a 2.65% decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 88,227 shares of company stock valued at $6,020,595. Company insiders own 2.40% of the company's stock.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.